Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium
Nautilus Biotechnology joined SEEDS, a four-year ARPA-H-funded consortium awarded up to $51.7 million to study protein misfolding in Alzheimer's disease and cancer. Nautilus expects to receive up to $6 million over the program to deploy its Voyager Platform measuring proteoforms of tau and EWS::FLI1, starting with Alzheimer's disease and Ewing sarcoma.
Key figures
- Deal Value Usd
- 51700000
- Nautilus funding up to
- 6000000
- Program duration years
- 4
- Voyager shipment target
- mid-2027
- Planned assays by mid 2028
- 20
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.